November 1, 2022
BioTissue Completes Name Change
MIAMI, November 1, 2022— BioTissue Holdings Inc., announced today the completion of its name change from TissueTech, Inc. The change is part of a corporate-wide branding initiative launched earlier this year to better represent the company’s entire portfolio and pipeline of products. Pursuant to the name change, the former TissueTech, Inc. has become BioTissue Holdings Inc., and its subsidiaries BioTissue Inc. is now BioTissue Ocular Inc., and the former Amniox Medical, Inc. is now BioTissue Surgical Inc.
“For over 25 years, the BioTissue name has been representative of leadership in ocular regenerative healing. Our name change allows us to showcase how our experience and expertise extends into the surgical space under the same trusted brand,” said Ted Davis, president and CEO, BioTissue. “Also, healthcare professionals and their patients can rest assured that we will continue to deliver the same high-quality products on which they rely.”
BioTissue’s innovative amniotic membrane product families Prokera®, AmnioGraft®, AmnioGuard®, Neox®, and Clarix® will retain their trusted brand names. All these products use the company’s proprietary CryoTek® cryopreservation technology designed to retain the tissue’s structural and functional integrity.
Today, nearly 700,000 patients have been treated with BioTissue’s products and its scientific and clinical advancements have been documented in over 390 peer-reviewed publications. BioTissue continues to break new ground with multiple investigational new drug clinical trials underway to secure biologic license applications for specific indications to address unmet clinical needs in the ocular, orthopedics, and wound management markets.
About BioTissue Holdings Inc.
BioTissue is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing for ocular surface disease and in surgical, chronic wound, and musculoskeletal applications. BioTissue’s portfolio of cryopreserved amniotic membrane products use its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple investigational new drug clinical trials as the company pursues biologics license applications for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed nearly 700,000 human implants with its products and published over 390 peer-reviewed studies supporting BioTissue’s platform technology. Learn more at biotissue.com.
Heather Kowalczyk, APR
McDougall Communications for BioTissue
[email protected] or (585) 434-2148